arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Citius Pharmaceuticals, Inc.

CTXR
$0.68 ▲ +0.03 (+5.34%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
62 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Citius Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $15.2M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -51.9%
FCF / Share $-0.06
Trailing P/E
Price / Book 0.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

62-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.67M
↓ -57.7%
Net Income Profit after all expenses
$-9.39M
↑ +8.6%
FCF / Share Free cash flow per share
$-0.06
↑ +90.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Financial Health
5
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 62 quarters